Biotech took a double hit Friday when both of its two biggest companies traded lower by more than 4%. Amgen (AMGN) was off on very disappointing news about a Vectibix drug trial, and Genentech (DNA), with one week left in the quarter, warned the investment community to expect flat revenues for its first quarter. >>> Discuss This Story
